Cetuximab (anti-EGFR)
CAS No. 205923-56-4
Cetuximab (anti-EGFR)( C225 )
Catalog No. M21142 CAS No. 205923-56-4
Cetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 260 | In Stock |
|
| 5MG | 434 | In Stock |
|
| 10MG | 627 | In Stock |
|
| 25MG | 981 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCetuximab (anti-EGFR)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
DescriptionCetuximab (anti-EGFR) is an inhibitor of epidermal growth factor receptor (EGFR).
-
In Vitro——
-
In Vivo——
-
SynonymsC225
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Areacancer
-
IndicationColorectal Cancer
Chemical Information
-
CAS Number205923-56-4
-
Formula Weight2756.23
-
Molecular FormulaC107H179N35O36S7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Huang S M Bock J M Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation Apoptosis and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res 1999 59(8):1935-1940.
molnova catalog
related products
-
Erlotinib
A potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.
-
CHF5074
CHF5074, a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).
-
ZD-4190
ZD-4190 is a inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling used for the treatment of cancer.
Cart
sales@molnova.com